Navigation Links
ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease
Date:2/26/2009

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit Therapeutics has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArray(TM) family of products that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit Therapeutics has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers.

In parallel, ExonHit Therapeutics is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising preclinical compounds. ExonHit Therapeutics also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides ongoing research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ISIN: FR0004054427; ticker: ALEHT) since November 17, 2005. For more information, please visit http://www.exonhit.com.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on manageme
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...swire-USNewswire/ -- The Department of Health toda...f priority groups that did not have previous acces...being held statewide on Nov. 20-22. Friday,s clini...y, Nov. 21, will be 8 a.m. to 2 p.m. On Sunday, No....m. ,, Individuals in the recommended target g...
(Date:11/20/2009)...e/ -- Reportlinker.com announces that a new market..., Pipettes & Pipettors - A Global Market Pe...64373/Pipettes--Pipettors---A-Global-Market-Perspe...&utm_campaign=prnewswire ,, Pipettes and ...esearch laboratory. Large-scale applications in li...
(Date:11/20/2009)...e/ -- Reportlinker.com announces that a new market..., Global Markets for Assisted Reproductive Devi...4742/Global-Markets-for-Assisted-Reproductive-Devi...=pr&utm_campaign=prnewswire ,, Global Mar... Countries in Europe and Japan. This report includ...
Breaking Medicine Technology:Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Military Moms Get The Baby Shower They Missed 57715 1Military Moms Get The Baby Shower They Missed 57715 2Military Moms Get The Baby Shower They Missed 57715 3Military Moms Get The Baby Shower They Missed 57715 4deCODE Discovers Four New Risk Factors for Prostate Cancer 5020 1deCODE Discovers Four New Risk Factors for Prostate Cancer 5020 2deCODE Discovers Four New Risk Factors for Prostate Cancer 5020 3deCODE Discovers Four New Risk Factors for Prostate Cancer 5020 4UCLA scientists make paralyzed rats walk again after spinal cord injury 9985 1UCLA scientists make paralyzed rats walk again after spinal cord injury 9985 2
...tics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ...in the November 1, 2008 issue the results of a stu...the use of short-course CHOP-R,followed by Zevalin...ab as,first-line treatment in follicular non-Hodgk...erapeutic regimen increased the complete,responses...
... and Improvement in Heart Failure in a ...Nov. 9 Celladon Corporation announced,today resul...AR(R), a,genetically-targeted enzyme replacement t...uct was safe and demonstrating improvement across ..."Calcium Up-Regulation by,Percutaneous Administrat...
Other Medicine Technology:Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma 2Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma 3Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma 4Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions 2Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions 3Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions 4
(Date:11/23/2009)... When Ryan Bailey, a leader in his...ame to the leader in Refractive Surgery, Dr. Rajes...cussion regarding his competitive lifestyle, time ...specific eye parameters. Dr. Khanna then performed...s) November 23, 2009 -- Ryan Bailey won a silver m...
(Date:11/23/2009)... Latham & Phillips Southeaster...omers find the new and used ophthalmic instruments...stomers the opportunity to view a large variety of...heastern Division,s new website enables the compan...ive pricing. Because of the variety of products t...
(Date:11/22/2009)...in known to stimulate blood vessel growth has now ...th in the development of polyps that characterize ... by Johns Hopkins researchers suggests. The findin...el therapies to treat this form of the disease, wh...Chronic sinusitis, a constant irritation and swell...
(Date:11/22/2009)...S Nov. 23, 2009 UT Southwestern Medical Center i...nstitutes of Health to share $56 million over five... (ICAC). , The ICAC, which receives funding thr...nfectious Diseases, investigates novel treatments ...ecca Gruchalla, chief of allergy and immunology at...
(Date:11/22/2009)... World Famous Lasik surgeon, Dr. G...y to an ART in his pursuit for vision beyond 20/20...ternational clientel and is widely published in te... Jacksonville, FL (PRWEB) November 22, 2009... has been selected by Goldline Research as one of...
Breaking Medicine News(10 mins):Health News:Olympic Silver Medalist, Men's Water Polo Star Ryan Bailey Strikes Gold 2Health News:Ophthalmic Equipment Distributor, Latham & Phillips SE Division, Unveils Website 2Health News:Ophthalmic Equipment Distributor, Latham & Phillips SE Division, Unveils Website 3Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 2Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 3Health News:UT Southwestern receives continued NIH funding for Inner City Asthma Consortium 2Health News:Dr. Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 2
... ZyDoc Medical Transcription has been awarded a...service to the State of Colorado Department of Hum...ueblo. , Hauppauge, NY (P...or the State of Colorado Department of Human Servi...
... Ross University School of Medicine will add se...Danbury Hospital in Danbury, CT. , ...9-- Ross University School of Medicine is pleased ...ments will be located at Danbury Hospital in Danbu...
...ary Wilson, founding member of the world,s most fa...d of nearly 500 at the Lupus Foundation of Ameri...on Tuesday, May 12, 2009 with her signature flair .../www.newscom.com/cgi-bin/prnh/20090513/DC15633-a ...
...atient Access To Medical Care And Critical Researc...ies Union and the Public Patent Foundation at Benj...suit today charging that patents on two human gene... along the genes, known as BRCA1 and BRCA2, are re...
...Eye Care Centers of America, Inc. (ECCA) announced... of ECCA,s 10-3/4 percent Senior Subordinated Note...counts managed and/or advised by DDJ Capital Manag... consummated on April 14, 2009. , , About Eye C...
...e UC Davis Center for Healthcare Policy and Resear...cervical intraepithelial neoplasia (abnormal cervi...nce of the disease or invasive cervical cancer. Th...ng-term risks of subsequent abnormal cell growth o...
Other Medicine News:Health News:ZyDoc Medical Transcription Wins Colorado Mental Health Institute Contract Award 2Health News:ZyDoc Medical Transcription Wins Colorado Mental Health Institute Contract Award 3Health News:Ross University School of Medicine Expands Clinical Rotations on East Coast 2Health News:Mary Wilson Brings the Crowd to Their Feet at the Sixth Annual Lupus Foundation of America Awards Gala 2Health News:Mary Wilson Brings the Crowd to Their Feet at the Sixth Annual Lupus Foundation of America Awards Gala 3Health News:ACLU Challenges Patents on Breast Cancer Genes 2Health News:ACLU Challenges Patents on Breast Cancer Genes 3Health News:ACLU Challenges Patents on Breast Cancer Genes 4Health News:Women with previous abnormal cervical cells at higher risk for recurrence and invasive cancer 2Health News:Women with previous abnormal cervical cells at higher risk for recurrence and invasive cancer 3
...io-Dot SF (slot format) microfiltration units prov...ucleic acid in solution onto nitrocellulose or Zet...be accommodated by using interchangeable templates...slot format Bio-Dot SF apparatus. Each is availabl...
Dot Blotting Apparatus
...h vacuum stage, porous vacuum plate, reservoir sea...lid, instructions. The Model 785 vacuum blotter q...n agarose gel onto a nylon membrane. Because it ge...leic acid samples can be separated on a gel, trans...
Mini Trans-Blot
Medicine Products: